Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22188914 | 0.85 | POLB (0.62) | MAPTNPC1MCL1CDK2POLB | |
| SCHEMBL5327849 | 0.80 | CDK2 (0.56) | MAPTCDK2POLBL3MBTL1KMT2A | |
| SCHEMBL6488744 | 0.80 | MAPT (0.49) | MAPTNPC1MCL1CDK2POLB | |
| SCHEMBL22188908 | 0.80 | ALDH1A1 (0.56) | MAPTCDK2POLBKMT2AMEN1 | |
| SCHEMBL9486190 | 0.79 | POLB (0.47) | MAPTCDK2POLBKMT2AMEN1 | |
| SCHEMBL9158566 | 0.77 | EGFR (0.61) | MAPTNPC1MCL1CDK2POLB | |
| SCHEMBL7508094 | 0.77 | CDK2 (0.46) | MAPTNPC1MCL1CDK2POLB | |
| SCHEMBL29263665 | 0.77 | NR4A2 (0.59) | MAPTNPC1CDK2POLBKMT2A | |
| SCHEMBL27709706 | 0.77 | CDK2 (0.46) | MAPTNPC1MCL1CDK2POLB | |
| SCHEMBL9485938 | 0.76 | MAPK1 (0.60) | MAPTPOLBL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752585-B2 | Process for the preparation of Zafirlukast and analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20200216390-A1 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752585-B2 | Process for the preparation of Zafirlukast and analogs thereof | CHUK, HRH2, CTSH | MAPT 3963/4885NPC1 3880/4885MCL1 535/4885 |
| US-20200216390-A1 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF | CHUK, CTSH, HRH2 | MAPT 3838/4885NPC1 3927/4885MCL1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.